During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
An analysis of B cell adaptive immune receptor sequences in 10 individuals uncovered exceptionally diverse antibody repertoires with a subset of shared antibody clonotypes.
The researchers hope the datasets from their study can help to explain the effects of disease-associated variants on specific cell types of the immune system.
OMI researchers will apply and validate 1CellBio's inDrop system to generate predictive data for patients with undiagnosed immune dysfunction conditions.
The researchers characterized how gene therapy affects the immune cell repertoires and microbiomes of X-linked severe combined immunodeficiency patients.
